[Adrenolytic drugs and the restoration of renal vasodilator and water-salt capacity of dopamine under water-salt deprivation conditions].
Agnoli
G C
GC
Cacciari
M
M
Garutti
C
C
Lenzi
P
P
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D004231:Diuresis / Q000187:drug effects; D004298:Dopamine / Q000494:pharmacology* / Q000502:physiology; D004347:Drug Interactions; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005947:Glucose / Q000009:adverse effects; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D007686:Kidney Tubules, Distal / Q000187:drug effects* / Q000503:physiopathology; D009318:Natriuresis / Q000187:drug effects; D011141:Polyuria / Q000139:chemically induced / Q000150:complications; D011224:Prazosin / Q000494:pharmacology / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects; D012964:Sodium / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014883:Water-Electrolyte Imbalance / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D012964:Sodium; D005947:Glucose; D004298:Dopamine; D011224:Prazosin